Coldstream Laboratories appoints vp of manufacturing
Dr Vickie Hall takes responsibility for manufacturing, facilities and warehouse operations
In her new position, Hall will assume responsibility of Coldstream's manufacturing, facilities, and warehouse operations in Lexington, Kentucky.
Hall brings to Coldstream more than 20 years of experience in managing research, product development, manufacturing and operations for vaccines and pharmaceuticals. Most recently, she served as executive director of manufacturing science and technology at Ben Venue Laboratories, a subsidiary of the Boehringer Ingelheim Corporation.
You may also like
Regulatory
Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria
Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Human-machine symbiosis: why Industry 5.0 is the future of pharmaceutical manufacturing
Industry 5.0 is reshaping pharmaceutical manufacturing by fostering human-machine collaboration, addressing workforce shortages and making advanced automation accessible to all through innovative models such as robot rental
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases